Literature DB >> 20369969

Dynamic multidrug therapies for hiv: optimal and sti control approaches.

B M Adams1, H T Banks, Hee-Dae Kwon, Hien T Tran.   

Abstract

We formulate a dynamic mathematical model that describes the interaction of the immune system with the human immunodeficiency virus (HIV) and that permits drug "cocktail " therapies. We derive HIV therapeutic strategies by formulating and analyzing an optimal control problem using two types of dynamic treatments representing reverse transcriptase (RT) in hibitors and protease inhibitors (PIs). Continuous optimal therapies are found by solving the corresponding optimality systems. In addition, using ideas from dynamic programming, we formulate and derive suboptimal structured treatment interruptions (STI)in antiviral therapy that include drug-free periods of immune-mediated control of HIV. Our numerical results support a scenario in which STI therapies can lead to long-term control of HIV by the immune response system after discontinuation of therapy.

Entities:  

Year:  2004        PMID: 20369969     DOI: 10.3934/mbe.2004.1.223

Source DB:  PubMed          Journal:  Math Biosci Eng        ISSN: 1547-1063            Impact factor:   2.080


  25 in total

1.  Strategic treatment interruptions during imatinib treatment of chronic myelogenous leukemia.

Authors:  Dana Paquin; Peter S Kim; Peter P Lee; Doron Levy
Journal:  Bull Math Biol       Date:  2010-06-09       Impact factor: 1.758

2.  Costs versus benefits: best possible and best practical treatment regimens for HIV.

Authors:  O Krakovska; L M Wahl
Journal:  J Math Biol       Date:  2007-01-05       Impact factor: 2.259

3.  Analysis of recruitment and industrial human resources management for optimal productivity in the presence of the HIV/AIDS epidemic.

Authors:  Kazeem O Okosun; Oluwole D Makinde; Isaac Takaidza
Journal:  J Biol Phys       Date:  2012-11-01       Impact factor: 1.365

4.  Using mathematical modeling and control to develop structured treatment interruption strategies for HIV infection.

Authors:  Eric S Rosenberg; Marie Davidian; H Thomas Banks
Journal:  Drug Alcohol Depend       Date:  2007-02-05       Impact factor: 4.492

5.  Reinforcement learning design for cancer clinical trials.

Authors:  Yufan Zhao; Michael R Kosorok; Donglin Zeng
Journal:  Stat Med       Date:  2009-11-20       Impact factor: 2.373

6.  Modelling and optimal control of immune response of renal transplant recipients.

Authors:  H T Banks; Shuhua Hu; Taesoo Jang; Hee-Dae Kwon
Journal:  J Biol Dyn       Date:  2012-02-01       Impact factor: 2.179

7.  Bifurcation thresholds and optimal control in transmission dynamics of arboviral diseases.

Authors:  Hamadjam Abboubakar; Jean Claude Kamgang; Leontine Nkague Nkamba; Daniel Tieudjo
Journal:  J Math Biol       Date:  2017-06-06       Impact factor: 2.259

8.  Is the pharmaceutical industry's preoccupation with the monotherapy drug model stifling the development of effective new drug therapies?

Authors:  Ian Edwin Cock
Journal:  Inflammopharmacology       Date:  2018-05-07       Impact factor: 4.473

9.  Dynamic models for estimating the effect of HAART on CD4 in observational studies: Application to the Aquitaine Cohort and the Swiss HIV Cohort Study.

Authors:  Mélanie Prague; Daniel Commenges; Jon Michael Gran; Bruno Ledergerber; Jim Young; Hansjakob Furrer; Rodolphe Thiébaut
Journal:  Biometrics       Date:  2016-07-26       Impact factor: 2.571

10.  Modelling HIV immune response and validation with clinical data.

Authors:  H T Banks; M Davidian; Shuhua Hu; Grace M Kepler; E S Rosenberg
Journal:  J Biol Dyn       Date:  2008-10       Impact factor: 2.179

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.